Home › Insurance › Medicare Part D 2027
Direct answer: In 2027, no Medicare drug plan can have a deductible over $700, and your out-of-pocket costs for covered Part D drugs are capped at $2,400. After you reach the cap, you pay $0 for covered drugs for the rest of the year. CMS projects stand-alone drug plan premiums will average about $36 a month.
By the numbers: The 2027 cap is $300 higher than 2026's $2,100, and the maximum deductible rises from $615 to $700; the national base beneficiary premium used for late penalties is $41.33, up from $38.99. Source: Medicare.gov and CMS (July 28, 2026)
“This payment option might help you manage your monthly expenses, but it doesn't save you money or lower your drug costs.” — Medicare.gov, What's the Medicare Prescription Payment Plan?
Updated 2026-10-16
$2,400 for covered drugs, up from $2,100 in 2026. It includes your deductible, coinsurance and copays, and certain payments made for you such as Extra Help. After you reach it you pay $0 for covered Part D drugs for the rest of 2027 (Medicare.gov).
CMS projects the average stand-alone Part D plan premium at about $36 a month in 2027 (from $35.09 in 2026), and the average drug premium inside Medicare Advantage plans at $7 (from $11.32). CMS says 88% of people without low-income help can get a basic plan for $10.30 or less.
1% of the national base beneficiary premium ($41.33 in 2027) for each full month you went without Part D or other creditable drug coverage, rounded to the nearest 10 cents. Fourteen months works out to $5.80 a month, added for as long as you have drug coverage. People with Extra Help don't pay it.
Instead of paying the pharmacy, you get a monthly bill: your new drug costs plus any unpaid balance, divided by the months left in the year. In Medicare's 2027 example, $600 a month of drug costs starting in January means bills of $200, $90.91, $150.91, then about $217.58 a month. There's no fee or interest, and it doesn't lower your total.
Fifteen Part D drugs, effective Jan. 1, 2027, including Ozempic, Rybelsus and Wegovy ($274 for a 30-day supply vs. a $959 list price in 2024), Trelegy Ellipta, Breo Ellipta, Xtandi, Ibrance, Linzess, Janumet and Tradjenta. What you pay still depends on your plan's copay or coinsurance.
No more than $35 for a one-month supply of each covered insulin product, with no deductible, even if you get Extra Help. A three-month supply is generally no more than $105 (Medicare.gov).
Generally no. CMS says people who want to keep their current coverage generally don't need to re-enroll. Open enrollment runs Oct. 15 to Dec. 7, 2026, and changes start Jan. 1, 2027. If you switch plans, Medicare Prescription Payment Plan participation ends and you must sign up again with the new plan.
As of Oct. 16, 2026
Uses the 2027 standard benefit from Medicare.gov. Nothing you type leaves your phone.
Compare plans on your own drug list before December 7. The $2,400 cap and $700 deductible limit are the same in every plan, so the differences that matter are the premium, which of your drugs are on the plan's list, and its copays at your pharmacy. If your costs come early in the year, the free Prescription Payment Plan can spread them out without changing the total.
The math:
Sources: Medicare.gov Part D costs · CMS Sept. 28, 2026 release · Medicare.gov Payment Plan fact sheet
A best fit for the situation described, not financial advice or a buy/sell recommendation. Partner links never change a pick.
| Item | 2026 | 2027 |
|---|---|---|
| Maximum plan deductible | $615 | $700 |
| Out-of-pocket cap, covered drugs | $2,100 | $2,400 |
| Coinsurance after the deductible (standard benefit) | 25% | 25% |
| National base beneficiary premium (late penalty base) | $38.99 | $41.33 |
| Average stand-alone drug plan premium (CMS projection) | $35.09 | about $36 |
| Average drug premium in Medicare Advantage plans | $11.32 | $7 |
| Average Medicare Advantage premium (all plans) | $14.37 | $12.00 |
| Medicare Advantage plans nationwide | 5,553 | about 5,532 |
| Covered insulin, per product per month | up to $35 | up to $35 |
Sources: Medicare.gov Part D costs · CMS July 28, 2026 fact sheet · CMS Sept. 28, 2026 release · Medicare.gov insulin. CMS also projects 88% of people without low-income help can get a basic stand-alone plan for $10.30 a month or less. The 2027 Part B premium and deductible had not been announced when we checked (Medicare.gov still lists 2026's $202.90 and $283).
“Your monthly bill is based on what you would have paid for any prescriptions you get, plus your previous month’s balance, divided by the number of months left in the year.” — Medicare.gov
Sources: Medicare.gov Payment Plan fact sheet · 42 CFR 423.137
Sources: Medicare.gov Part D costs · CMS July 28, 2026 fact sheet
These are the prices Medicare drug plans pay for a 30-day supply, not your copay. Your share depends on your plan, but coinsurance is figured on a lower price, and every Part D plan must include these drugs on its list.
| Drug (commonly treated conditions) | 2027 negotiated, 30 days | 2024 list price | Discount | Part D users, 2024 |
|---|---|---|---|---|
| Ozempic; Rybelsus; Wegovy Type 2 diabetes; type 2 diabetes and cardiovascular disease; cardiovascular disease and obesity/overweight | $274 | $959 | 71% | 2,282,000 |
| Trelegy Ellipta Asthma; COPD | $175 | $654 | 73% | 1,269,000 |
| Xtandi Prostate cancer | $7,004 | $13,480 | 48% | 35,000 |
| Pomalyst Kaposi sarcoma; multiple myeloma | $8,650 | $21,744 | 60% | 14,000 |
| Ofev Idiopathic pulmonary fibrosis | $6,350 | $12,622 | 50% | 24,000 |
| Ibrance Breast cancer | $7,871 | $15,741 | 50% | 16,000 |
| Linzess Chronic idiopathic constipation; IBS with constipation | $136 | $539 | 75% | 632,000 |
| Calquence Chronic lymphocytic leukemia/small lymphocytic lymphoma; mantle cell lymphoma | $8,600 | $14,228 | 40% | 15,000 |
| Austedo; Austedo XR Chorea in Huntington's disease; tardive dyskinesia | $4,093 | $6,623 | 38% | 27,000 |
| Breo Ellipta Asthma; COPD | $67 | $397 | 83% | 626,000 |
| Xifaxan Hepatic encephalopathy; IBS with diarrhea | $1,000 | $2,696 | 63% | 105,000 |
| Vraylar Bipolar I disorder; major depressive disorder; schizophrenia | $770 | $1,376 | 44% | 118,000 |
| Tradjenta Type 2 diabetes | $78 | $488 | 84% | 274,000 |
| Janumet; Janumet XR Type 2 diabetes | $80 | $526 | 85% | 239,000 |
| Otezla; Otezla XR Oral ulcers in Behcet's disease; plaque psoriasis; psoriatic arthritis | $1,650 | $4,722 | 65% | 31,000 |
CMS: about 5.3 million of 53 million Part D enrollees used these drugs in 2024 and paid $1.7 billion out of pocket; CMS estimates enrollees would save about $685 million in 2027 under the standard benefit. These 15 join 10 drugs whose negotiated prices started in 2026. Ozempic package example: $276.78 for a 4 mg/3 mL pen. Source: CMS 2027 negotiated prices
| State | Avg. MA premium | MA plans | Drug plans | Lowest drug plan | Can pay less than 2026 |
|---|---|---|---|---|---|
| Alabama | $7.76 | 113 | 11 | $5.30 | 67.98% |
| Alaska | n/a | n/a | 9 | $5.30 | 100% |
| American Samoa | n/a | n/a | 1 | $10.30 | 0% |
| Arizona | $2.81 | 148 | 9 | $5.30 | 38.67% |
| Arkansas | $1.47 | 84 | 11 | $5.30 | 47.21% |
| California | $14.12 | 394 | 10 | $5.30 | 100% |
| Colorado | $9.10 | 104 | 8 | $5.30 | 43.36% |
| Connecticut | $25.31 | 48 | 10 | $13.30 | 100% |
| Delaware | $14.33 | 38 | 9 | $5.30 | 100% |
| District of Columbia | $16.91 | 15 | 9 | $5.30 | 100% |
| Florida | $2.13 | 560 | 11 | $5.30 | 52.69% |
| Georgia | $2.99 | 161 | 9 | $5.30 | 51.65% |
| Guam | n/a | n/a | 1 | $10.30 | 0% |
| Hawaii | $53.04 | 46 | 8 | $10.30 | 40.97% |
| Idaho | $37.93 | 44 | 8 | $5.30 | 100% |
| Illinois | $7.11 | 136 | 10 | $5.30 | 42.94% |
| Indiana | $9.27 | 140 | 8 | $5.30 | 100% |
| Iowa | $11.21 | 64 | 9 | $5.30 | 100% |
| Kansas | $5.90 | 80 | 12 | $5.30 | 51.46% |
| Kentucky | $4.90 | 123 | 8 | $5.30 | 100% |
| Louisiana | $6.71 | 124 | 8 | $5.30 | 65.79% |
| Maine | $22.07 | 50 | 8 | $5.30 | 55% |
| Maryland | $23.82 | 47 | 9 | $5.30 | 100% |
| Massachusetts | $37.80 | 97 | 10 | $13.30 | 100% |
| Michigan | $16.21 | 181 | 11 | $5.30 | 44.99% |
| Minnesota | $59.40 | 53 | 9 | $5.30 | 100% |
| Mississippi | $4.08 | 102 | 9 | $5.30 | 58.93% |
| Missouri | $4.24 | 174 | 9 | $5.30 | 100% |
| Montana | $16.12 | 23 | 9 | $5.30 | 100% |
| Nebraska | $14.14 | 48 | 9 | $5.30 | 100% |
| Nevada | $0.56 | 98 | 9 | $5.30 | 59.16% |
| New Hampshire | $17.18 | 20 | 8 | $5.30 | 48.29% |
| New Jersey | $20.09 | 72 | 11 | $5.30 | 100% |
| New Mexico | $4.58 | 61 | 10 | $5.30 | 67.69% |
| New York | $30.79 | 227 | 9 | $37.30 | 100% |
| North Carolina | $6.19 | 179 | 11 | $5.30 | 52.96% |
| North Dakota | $41.44 | 17 | 9 | $5.30 | 100% |
| Northern Mariana Islands | n/a | n/a | 1 | $10.30 | 100% |
| Ohio | $9.00 | 180 | 9 | $5.30 | 100% |
| Oklahoma | $8.06 | 81 | 9 | $5.30 | 69.47% |
| Oregon | $26.30 | 100 | 8 | $5.30 | 56.54% |
| Pennsylvania | $20.07 | 338 | 8 | $5.30 | 100% |
| Puerto Rico | $0.00 | 63 | 3 | $9.30 | 100% |
| Rhode Island | $37.64 | 22 | 10 | $13.30 | 100% |
| South Carolina | $3.98 | 97 | 8 | $5.30 | 46.24% |
| South Dakota | $56.04 | 22 | 9 | $5.30 | 100% |
| Tennessee | $11.73 | 155 | 11 | $5.30 | 58.01% |
| Texas | $4.27 | 421 | 10 | $5.30 | 54.51% |
| Utah | $9.16 | 51 | 8 | $5.30 | 100% |
| Vermont | $7.79 | 5 | 10 | $13.30 | 100% |
| Virgin Islands | n/a | n/a | 1 | $106.30 | 100% |
| Virginia | $6.67 | 148 | 9 | $5.30 | 37.97% |
| Washington | $22.75 | 120 | 8 | $5.30 | 58.39% |
| West Virginia | $15.36 | 70 | 8 | $5.30 | 100% |
| Wisconsin | $19.67 | 103 | 8 | $5.30 | 34.05% |
| Wyoming | $69.23 | 8 | 9 | $5.30 | 100% |
Source: CMS state fact sheets. “Can pay less” = share of current stand-alone drug plan members with access to a lower premium than they paid in 2026. n/a = no Advantage data in CMS's sheet (Alaska and most territories).
Why trust this: every number links to the CMS or Medicare.gov document it comes from, with the date we read it. The Payment Plan math reproduces Medicare's own 2027 example to the cent, and the state numbers come straight from CMS's 2027 state fact sheets.
Not insurance advice. We republish CMS and Medicare.gov figures with dates and do the arithmetic on what you type. Free, unbiased help: your State Health Insurance Assistance Program (SHIP) or 1-800-MEDICARE.
$2,400 for covered drugs, up from $2,100 in 2026. It includes your deductible, coinsurance and copays, and certain payments made for you such as Extra Help. After you reach it you pay $0 for covered Part D drugs for the rest of 2027 (Medicare.gov).
CMS projects the average stand-alone Part D plan premium at about $36 a month in 2027 (from $35.09 in 2026), and the average drug premium inside Medicare Advantage plans at $7 (from $11.32). CMS says 88% of people without low-income help can get a basic plan for $10.30 or less.
1% of the national base beneficiary premium ($41.33 in 2027) for each full month you went without Part D or other creditable drug coverage, rounded to the nearest 10 cents. Fourteen months works out to $5.80 a month, added for as long as you have drug coverage. People with Extra Help don't pay it.
Instead of paying the pharmacy, you get a monthly bill: your new drug costs plus any unpaid balance, divided by the months left in the year. In Medicare's 2027 example, $600 a month of drug costs starting in January means bills of $200, $90.91, $150.91, then about $217.58 a month. There's no fee or interest, and it doesn't lower your total.
Fifteen Part D drugs, effective Jan. 1, 2027, including Ozempic, Rybelsus and Wegovy ($274 for a 30-day supply vs. a $959 list price in 2024), Trelegy Ellipta, Breo Ellipta, Xtandi, Ibrance, Linzess, Janumet and Tradjenta. What you pay still depends on your plan's copay or coinsurance.
No more than $35 for a one-month supply of each covered insulin product, with no deductible, even if you get Extra Help. A three-month supply is generally no more than $105 (Medicare.gov).
Generally no. CMS says people who want to keep their current coverage generally don't need to re-enroll. Open enrollment runs Oct. 15 to Dec. 7, 2026, and changes start Jan. 1, 2027. If you switch plans, Medicare Prescription Payment Plan participation ends and you must sign up again with the new plan.
Facts, not insurance advice. We don't sell insurance or provide quotes; confirm coverage and requirements with the insurer, an agent or your state insurance department.